SAN DIEGO, May 7, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Bank of
America Merrill Lynch 2015 Health Care Conference in Las Vegas, on Thursday,
May 14, 2015 at 10:40 a.m.
PT/1:40 p.m. ET.
David Ramsay, chief financial
officer, will provide a corporate overview.
The presentation will be webcast through the "Investors" section
of www.halozyme.com, and a recording will be made available for 90
days following the event. To access the live webcast, please log on
to Halozyme's website approximately 15 minutes prior to the
presentation to register and download any necessary audio
software.
About Halozyme
Halozyme Therapeutics is a biotechnology company focused on
developing and commercializing novel oncology therapies that target
the tumor microenvironment. Halozyme's lead proprietary program, an
investigational drug PEGPH20, applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor. PEGPH20
is currently in development for metastatic pancreatic cancer and
non-small cell lung cancer and has potential across additional
cancers in combination with different types of therapies. In
addition to its proprietary product portfolio, Halozyme has
established value-driving partnerships with leading pharmaceutical
companies including Roche, Pfizer, Janssen and Baxter for its drug delivery platform,
ENHANZE™, which enables biologics and small molecule compounds that
are currently administered intravenously to be delivered
subcutaneously. Halozyme is headquartered in San Diego. For
more information, visit www.halozyme.com.
Contacts:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Jim Mazzola
Halozyme Therapeutics
858-704-8122
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-2015-health-care-conference-300079941.html
SOURCE Halozyme Therapeutics, Inc.